Higher dose of breast cancer drug shows promise in early trial
NCT ID NCT00585507
First seen May 27, 2026 · Last updated Jun 19, 2026 · Updated 5 times
Summary
This phase II trial is testing a higher dose (500 mg) of the drug fulvestrant (Faslodex) as a first hormonal treatment for postmenopausal women with hormone receptor positive metastatic breast cancer. The study aims to see if this higher dose improves clinical benefit compared to standard doses. Forty women are enrolled to receive injections on a monthly schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Lowell General Hospital
Lowell, Massachusetts, 01854, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02114, United States
-
South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fulvestrant (Faslodex)
What this could lead to
If successful, this higher dose of fulvestrant could improve control of metastatic breast cancer, offering a more effective first-line hormonal therapy option.
What could go wrong
This is a small phase II trial with only 40 participants, so results may not apply broadly. The higher dose could also increase side effects without improving outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.